肠道菌群与免疫检查点抑制剂研究进展

Research Progress of Intestinal Microbiota and Immune Checkpoint Inhibitors

肠道菌群能够通过局部或全身炎性反应影响肿瘤的发生、发展以及治疗。目前,肠道菌群在肿瘤治疗中的作用越来越显著,研究发现,肠道菌群影响实体瘤免疫检查点抑制剂治疗反应,但造成个体间免疫反应差异的机制尚不清楚。有学者认为,肠道菌群在其中可能发挥潜在的调节作用。例如嗜黏蛋白-艾克曼菌、乳酸杆菌及双歧杆菌等都具有调节肿瘤细胞及免疫细胞功能,并促进多种细胞因子的产生,进而提高免疫检查点抑制剂治疗效果。因此,本文就肠道菌群对肿瘤细胞及免疫细胞的影响和目前肠道菌群与免疫检查点抑制剂的研究现状做一阐述。

Intestinal microbiota are able to influence tumor initiation,progression,as well as therapy through local or systemic inflammation.Currently,the role of intestinal microbiota in cancer treatment is becoming increasingly significant,and investigators have found that intestinal microbiota affect the responsiveness of solid tumor to immune checkpoint inhibitor treatment,but the mechanisms responsible for inter-individual differences in immune responses are unclear.Some scholars believe that gut microbiota may play a potential regulatory role in it,such as Akkermansia muciniphila,lactobacillus and bifidobacterium can regulate the function of tumor cells and immune cells,and promote the production of a variety of cytokines,thereby improving the therapeutic effect of immune checkpoint inhibitors.Therefore,in this paper,the effects of gut microbiota on tumor cells and immune cells,as well as the current status of research on gut microbiota and immune checkpoint inhibitors are described.